Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/21567| Title: | Neratinib after trastuzumab in patients with HER2-positive breast cancer Reply | Authors: | Chan, Arlene BUYSE, Marc Yao, Bin |
Issue Date: | 2016 | Publisher: | ELSEVIER SCIENCE INC | Source: | LANCET ONCOLOGY, 17 (5), p. E176-E177 | Notes: | [Chan, Arlene] Breast Canc Res Ctr Western Australia, Perth, WA, Australia. [Buyse, Marc] Int Inst Drug Dev, San Francisco, CA USA. [Buyse, Marc] Hasselt Univ, I BioStat, Hasselt, Belgium. [Yao, Bin] Puma Biotechnol Inc, Los Angeles, CA USA. | Document URI: | http://hdl.handle.net/1942/21567 | ISSN: | 1470-2045 | e-ISSN: | 1474-5488 | ISI #: | 000374829800006 | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2017 |
| Appears in Collections: | Research publications |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| chan 1.pdf Restricted Access | Published version | 144.07 kB | Adobe PDF | View/Open Request a copy |
WEB OF SCIENCETM
Citations
5
checked on Apr 24, 2024
Page view(s)
6
checked on Sep 5, 2022
Download(s)
4
checked on Sep 5, 2022
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.